Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

NCT01579474 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: BI 201335 high dose
DRUG: BI 201335 low dose
DRUG: BI 201335 high dose
DRUG: BI 201335 high dose

Sponsor

Boehringer Ingelheim